Expanded Access to Rovalpituzumab Tesirine
- Conditions
- Small Cell Lung Cancer
- Registration Number
- NCT03503890
- Lead Sponsor
- AbbVie
- Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Rovalpituzumab Tesirine prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- The participant must not be eligible for a Rovalpituzumab Tesirine clinical trial.
- Pediatric participants may be evaluated on a case by case basis.
Exclusion Criteria
- None.
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method